KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Research & Development (2016 - 2025)

Alnylam Pharmaceuticals' Research & Development history spans 16 years, with the latest figure at $372.2 million for Q4 2025.

  • For Q4 2025, Research & Development rose 24.0% year-over-year to $372.2 million; the TTM value through Dec 2025 reached $1.3 billion, up 17.19%, while the annual FY2025 figure was $1.3 billion, 17.19% up from the prior year.
  • Research & Development reached $372.2 million in Q4 2025 per ALNY's latest filing, up from $358.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $372.2 million in Q4 2025 to a low of $169.9 million in Q1 2022.
  • Average Research & Development over 5 years is $256.3 million, with a median of $257.1 million recorded in 2023.
  • Peak YoY movement for Research & Development: surged 35.96% in 2021, then decreased 8.61% in 2022.
  • A 5-year view of Research & Development shows it stood at $229.0 million in 2021, then rose by 14.4% to $262.0 million in 2022, then rose by 3.86% to $272.1 million in 2023, then increased by 10.3% to $300.2 million in 2024, then increased by 24.0% to $372.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Research & Development are $372.2 million (Q4 2025), $358.8 million (Q3 2025), and $323.6 million (Q2 2025).